ABIGAIL FINKENAUER: Open Payments
NPI 1548954761 · MIDDLETOWN, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,484 in 110 payments from 17 companies in 2025. Trend: 2023 $283 · 2024 $1,169 · 2025 $2,484
Food & beverage: $2,299Education: $185
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 19 | $463 |
| ABBVIE INC. | 23 | $329 |
| Janssen Biotech, Inc. | 14 | $309 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $272 |
| Novartis Pharmaceuticals Corporation | 9 | $210 |
| Organon LLC | 5 | $163 |
| GENZYME CORPORATION | 7 | $134 |
| Galderma Laboratories, L.P. | 6 | $111 |
| UCB, Inc. | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
Products named: OTEZLA, TREMFYA, DUPIXENT, SKYRIZI, RINVOQ, Bimzelx, ILUMYA, COSENTYX.
Industry payments across RI — which companies pay providers there.
